Translate Bio, Inc. operates as a therapeutics company. The Company develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio serves patients in the State of Massachusetts.

Current Report (Form 8-K | Period ending 2024-11-04)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Translate Bio Inc (TBIO US)

Current Report (Form 8-K | Period ending 2024-11-04)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-10-23)

Current Report (Form 8-K | Period ending 2024-09-10)

Current Report (Form 8-K | Period ending 2024-08-27)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)